Journal article
The ubiquitin-proteasome system in prostate cancer and its transition to castration resistance
Urologic oncology, Vol.30(6), pp.752-761
11/01/2012
DOI: 10.1016/j.urolonc.2010.03.013
PMID: 20580272
Abstract
Prostate cancer is the most common carcinoma in the male population. In its initial stage, the disease is androgen-dependent and responds therapeutically to androgen deprivation treatment but it usually progresses after a few years to an androgen-independent phase that is refractory to hormonal manipulations. The proteasome is a multi-unit protease system that regulates the abundance and function of a significant number of cell proteins, and its inhibition results in cancer cell growth inhibition and apoptosis and is already exploited in the clinic with the use of proteasome inhibitor bortezomib in multiple myeloma. In order to be recognized by the proteasome, a target protein needs to be linked to a chain of the small protein ubiquitin. In this paper, we review the role of ubiquitin-proteasome system (UPS) in androgen receptor-dependent transcription as well as in the castration resistant stage of the disease, and we discuss therapeutic opportunities that UPS inhibition offers in prostate cancer. (c) 2012 Elsevier Inc. All rights reserved.
Details
- Title: Subtitle
- The ubiquitin-proteasome system in prostate cancer and its transition to castration resistance
- Creators
- Ioannis A. Voutsadakis - Univ Hosp Larissa, Dept Med Oncol, Larisa, GreeceChristos N. Papandreou - Univ Hosp Larissa, Dept Med Oncol, Larisa, Greece
- Resource Type
- Journal article
- Publication Details
- Urologic oncology, Vol.30(6), pp.752-761
- Publisher
- Elsevier
- DOI
- 10.1016/j.urolonc.2010.03.013
- PMID
- 20580272
- ISSN
- 1078-1439
- eISSN
- 1873-2496
- Number of pages
- 10
- Language
- English
- Date published
- 11/01/2012
- Academic Unit
- Internal Medicine
- Record Identifier
- 9984806613602771
Metrics
2 Record Views